Management of Coats’ disease with RazumabTM (World’s first biosimilar ranibizumab) and laser photocoagulation: A case report

We report a case of a 19-year-old Indian male with stage 2 Coats’ disease who was managed with monthly intravitreal biosimilar ranibizumab injections (n=3) along with laser photocoagulation in the right eye. Post-treatment, significant reductions were seen in the exudation, angioma-like lesions, central macular thickness and edema in the retina. At the last follow-up at 9 months after intravitreal biosimilar ranibizumab initiation, distant vision improved from best corrected visual acuity (BCVA) of 5/60 at baseline to 6/18, and near vision from ‘not able to read’ to N/12 in the right eye. Keywords: Biosimilar, Coats’ disease, Laser photocoagulation, Ranibizumab.